Massive Response! Rubicon Research IPO Allotment Today- 25% GMP, 103x Subscription & Listing Date Insights!
Rubicon Research IPO Allotment: Rubicon Research Ltd. is all set to finalise its IPO share allotment status on Tuesday, October 14, 2025, after witnessing one of the strongest responses from Dalal Street investors this month. The ₹1,377.50 crore public issue, comprising both a fresh issue and an offer for sale, was subscribed an impressive 103.89 times by the end of bidding.
The Rubicon Research IPO allotment will determine which investors receive shares, with credit to demat accounts likely on October 15, and the company’s listing on the NSE and BSE expected on October 16, 2025.
Rubicon Research IPO GMP Today
As per market observers, Rubicon Research’s Grey Market Premium (GMP) stands at ₹118 per share as of October 14, 2025.
| Parameter | Value |
|---|---|
| Issue Price (Upper Band) | ₹485 |
| GMP (Approx.) | ₹118 |
| Expected Listing Price | ₹603 (₹485 + ₹118) |
| Implied Listing Gain | ~24% |
A 24–26% grey market premium indicates that the IPO could see a strong listing pop, assuming stable market sentiment. Analysts attribute the bullish GMP trend to both robust subscription numbers and a rebound in pharma stocks on Dalal Street over the past week.
Rubicon Research IPO Subscription Status
The IPO’s massive oversubscription signals strong demand across investor categories, particularly from institutional players. Here’s how the bids stacked up:
| Investor Category | Subscription (x times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 130.26x |
| Non-Institutional Investors (NIIs) | 97.61x |
| Retail Investors | 35.47x |
| Employees | 16.80x |
| Overall | 103.89x |
Such heavy participation — especially from QIBs — reflects institutional confidence in Rubicon’s growth potential amid a recovery in pharma valuations. Analysts note that robust fundamentals and a clean balance sheet have drawn strong investor interest.
Rubicon Research IPO Details at a Glance
| Particulars | Details |
|---|---|
| IPO Size | ₹1,377.50 crore |
| Fresh Issue | ₹500 crore (1.03 crore shares) |
| Offer for Sale (OFS) | ₹877.50 crore (1.81 crore shares) |
| Price Band | ₹461 – ₹485 per share |
| IPO Lot Size | 30 shares per lot |
| Minimum Retail Investment | ₹14,550 |
| Opening Date | October 9, 2025 |
| Closing Date | October 13, 2025 |
| Allotment Date | October 14, 2025 |
| Refunds / Credit to Demat | October 15, 2025 |
| Listing Date | October 16, 2025 |
| Exchanges | NSE, BSE |
| Registrar | MUFG Intime India Pvt Ltd |
Rubicon Research, incorporated in 1999, develops and manufactures differentiated pharmaceutical formulations. The company plans to utilise ₹310 crore from the IPO proceeds for prepayment of borrowings, and the remaining funds for inorganic growth, acquisitions, and general corporate purposes.
How to Check Rubicon Research IPO Allotment Status Online?
Investors who applied for the issue can check their Rubicon Research IPO allotment online via either the BSE website or the registrar portal (MUFG Intime India).
🔹 On BSE Website
- Visit: https://www.bseindia.com/static/investors/application_statuschecksystem.aspx
- Select “Equity” as issue type
- Choose “Rubicon Research Ltd.” from the dropdown
- Enter your application number or PAN
- Click ‘Search’ to view allotment status
🔹 On MUFG Intime India Portal
- Visit: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
- Select “Rubicon Research Limited” from the company list
- Enter PAN, Application Number, or DP/Client ID
- Click ‘Submit’ to check your allotment
Successful bidders will see shares credited to their demat accounts by October 1, 2025, while refunds for non-allottees will be processed the same day.
Company Outlook and Listing Expectations
Rubicon Research’s focus on innovative pharma formulations positions it well in India’s fast-evolving healthcare market. The company’s debt reduction plan, combined with a push toward inorganic expansion, could strengthen its long-term growth profile.
Experts suggest that, if listed near or above its implied GMP, the stock may trade in the ₹600–₹620 range on listing day. However, they also caution that post-listing performance will depend on market liquidity, Q2 earnings sentiment, and sector momentum.
Final Takeaway
The Rubicon Research IPO Allotment marks one of the most anticipated listings of this quarter. Backed by strong institutional demand, healthy GMP trends, and a promising growth roadmap, the company’s Dalal Street debut on October 16, 2025, could set the tone for the next wave of pharma IPOs this year.
Investors are advised to check their Rubicon Research IPO allotment status online, track listing-day volatility closely, and maintain realistic return expectations amid ongoing market fluctuations.
Click Here to know more Market & IPO Related News and Updates
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
